Rheumatology International最新文献

{"title":"Structural changes in the upper trapezius muscle of fibromyalgia patients identified by quantitative ultrasonography: a cross-sectional study.","authors":"Hatice Betigul Meral, Aylin Rezvani, Sena Tolu, Ahmet Usen, Muhammed Furkan Dasdelen","doi":"10.1007/s00296-025-05871-x","DOIUrl":"10.1007/s00296-025-05871-x","url":null,"abstract":"<p><p>The heterogeneity of symptoms among patients with fibromyalgia (FM) makes the development of standardized diagnostic criteria challenging. No imaging technique has reliably shown FM-related muscle changes to aid clinical assessment. This study aimed to quantitatively analyze the upper trapezius muscle in FM patients using B-mode ultrasonography and blob analysis and to examine its correlation with clinical parameters. A total of 34 female FM patients and 34 healthy controls were included in this cross-sectional study. B-mode ultrasonography was used to image the dominant-side upper trapezius muscle, and MATLAB-based blob analysis was performed to assess blob size, blob count, and echointensity. These measurements were correlated with disease severity indices, including the Central Sensitization Inventory (CSI), Visual Analog Scale (VAS) for pain, Fibromyalgia Impact Questionnaire (FIQ), 36-Item Short Form Survey (SF-36), and Beck Depression and Anxiety Inventories (BDI, BAI). FM patients had significantly higher total blob size (p < 0.001) and blob size per mm² (p < 0.001) than controls. Echointensity was significantly increased in the FM group (p = 0.009). Total blob size showed a moderate positive correlation with CSI scores (p = 0.002). Regression analysis indicated that pain-VAS was a significant predictor of total blob size per mm² (p < 0.001). Blob analysis demonstrated quantifiable muscle alterations in FM, supporting its potential role as an objective assessment tool. Given the correlation between muscle echotexture and FM severity, quantitative ultrasonography may contribute to a better understanding of FM pathophysiology.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"115"},"PeriodicalIF":3.2,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12014792/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144045495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low vaccination rates and awareness status in patients with rheumatoid arthritis: a nationwide cross-sectional survey study.","authors":"Ali Kirik, Nilay Şahin, Merve Baykul, Hatice Bodur, Tuba Güler, Remzi Çevik, Sevcan Uğur, Yunus Durmaz, Ali Yavuz Karahan, Gül Devrimsel, Nuran Öz, Mehmet Nur Kaya, Yeşim Çağlar, Mehmet Tuncay Duruöz, Kemal Nas","doi":"10.1007/s00296-025-05870-y","DOIUrl":"10.1007/s00296-025-05870-y","url":null,"abstract":"<p><p>To examine the pneumococcal, haemophilus influenza, hepatitis A virus (HAV), and hepatitis B virus (HBV) vaccine rates and and predictors of vaccination among a Türkiye population of rheumatoid arthritis (RA) patients. In this multicenter, cross-sectional study, vaccination levels and related factors were questioned by face-to-face survey method during routine clinical examination of patients with RA followed in different regions of Türkiye. All statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) software package, version 26. A total of 715 patients (mean age 53.1 ± 13 years), of whom 552 (77.2%) were women, were included in this study. The rate of vaccine awareness education in the whole patient group was 40.1%. The vaccination rates for influenza, pneumococcal, HAV, and HBV were 34.3%, 21.8%, 12.3%, and 28.5%, respectively. It was noteworthy that the level of vaccine awareness education was a positive predictive factor affecting vaccination in all vaccine types (p < 0.001, for all vaccine types). The rates of low income were higher in the vaccinated group for pneumococcal (p < 0.001) and haemophilus influenza (p = 0.011) vaccine than in the unvaccinated group. The participants with living in a rural area were significantly higher in the unvaccinated group for HAV and HBV vaccine than in the vaccinated group (p < 0.001). The frequency of less than two medical visits per year was significantly higher in the unvaccinated group for pneumococcal (p < 0.014) and haemophilus influenza (p < 0.001 ) and HBV vaccine (p = 0.009) than in the vaccinated group. multivariate analysis found that rural area (for Haemophilus influenza and HAV vaccines) and financial income (Pneumococcal vaccine) in specifically were associated with increased vaccination rates (p < 0.001). Additionally, the rate of vaccination education was significantly higher in the vaccinated group for all vaccine types, which is noteworthy as a result of the positive effect of education on vaccination (p < 0.001). Vaccination awareness education and rates are low in primary prevention for RA patients. Vaccination awareness training is important in increasing the level of vaccine rates.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"116"},"PeriodicalIF":3.2,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12014830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144027955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case-based review of IgA vasculitis complicated with gastrointestinal infections: insights from a norovirus-associated case in an adolescent.","authors":"Argyro Konstantopoulou, Ioannis Tsoliakos, Maria M Berikopoulou, Aikaterini Kiorsavva, Maria Theochari, Panagiota Drosatou, Anna Messaritaki, Dimitra Dimopoulou","doi":"10.1007/s00296-025-05876-6","DOIUrl":"10.1007/s00296-025-05876-6","url":null,"abstract":"<p><p>Immunoglobulin A vasculitis (IgAV), formerly known as Henoch-Schönlein purpura, is a self-limited leukocytoclastic vasculitis targeting small-sized vessels. It is the most common vasculitis in children, but also targets adults who have usually worse prognosis. It typically presents with purpuric rash, arthritis, colicky abdominal pain and potential renal involvement. Gastrointestinal (GI) manifestations, although frequent, may be severe and occasionally complicated by infections. We present a 11-year-old male with a recent diagnosis of IgAV who was admitted with severe abdominal pain, hematemesis and hematochezia. Stool analysis identified Norovirus as the causative pathogen for the severe gastrointestinal symptoms. Treatment with proton pump inhibitors, high-dose corticosteroids and intravenous fluids resulted in symptoms resolution and clinical improvement. In addition, a case-based review of the literature was conducted to evaluate the prevalence of GI infections occurring after the development of IgAV that may result in severe complications or disease relapses. Thirty-five patients with a median age of 14 years were included in our study. Among these patients, 42.9% were diagnosed with a concomitant bacterial gastrointestinal pathogen, followed by 25.7% with viral gastroenteritis and 17.1% with parasitic gastrointestinal disease. Treatment was individualized, with 48.5% receiving corticosteroids and 8.6% receiving immunosuppressive therapy. This case and case-based review highlights the significance of careful management and monitoring of patients with IgAV complicated by infections, because severe complications can cause significant morbidity and mortality especially in adults.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"114"},"PeriodicalIF":3.2,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143994076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of tocilizumab monotherapy for autoimmune hemolytic anemia associated with idiopathic multicentric Castleman disease: a case-based review.","authors":"Koji Suzuki, Mitsuhiro Akiyama, Koichi Saito, Kanako Shimanuki, Yuko Kaneko","doi":"10.1007/s00296-025-05880-w","DOIUrl":"10.1007/s00296-025-05880-w","url":null,"abstract":"<p><p>Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder characterized by generalized lymphadenopathy with distinctive histopathological features and systemic inflammation driven by excessive interleukin-6 (IL-6) production. Anemia due to chronic inflammation is a common manifestation of iMCD; however, this disease can also be complicated by autoimmune hemolytic anemia (AIHA). While tocilizumab (TCZ), an IL-6 receptor blockade, has demonstrated efficacy in treating iMCD, its therapeutic effect on AIHA secondary to iMCD remains unclear. Here, we report the first case of iMCD complicated by AIHA successfully treated with TCZ monotherapy, without the need for concurrent glucocorticoid therapy. Notably, AIHA improved along with the disappearance of autoantibodies under TCZ monotherapy, suggesting that IL-6 played a key role in the production of autoantibodies and causing AIHA secondary to iMCD. Furthermore, our literature review identified six other cases of iMCD with AIHA, five of which achieved favorable outcomes with a combination of TCZ and prednisolone, except for one case that developed anti-TCZ antibody. In two cases, AIHA improved without requiring an increase of prednisolone dose. These findings suggest that TCZ may represent a viable therapeutic option not only for iMCD itself but also for AIHA secondary to iMCD.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"113"},"PeriodicalIF":3.2,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143994088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The natural course of health-related quality of life in patients with clinically suspect arthralgia: a longitudinal study in progressors and non-progressors to rheumatoid arthritis.","authors":"Sterre Bour, Lucas Goossens, Sarah Khidir, Pascal de Jong, Annette van der Helm-van Mil, Maureen Rutten-van Mölken, Elise van Mulligen","doi":"10.1007/s00296-025-05865-9","DOIUrl":"10.1007/s00296-025-05865-9","url":null,"abstract":"<p><p>Individuals with clinically suspect arthralgia (CSA) are at risk of developing rheumatoid arthritis (RA). It is unknown whether CSA patients have a deprived health-related quality-of-life (HRQoL), how this develops over time, and whether it differs between those who develop RA and those who do not. Using three unique cohorts, we explored the course of HRQoL in CSA patients and after inflammatory arthritis (IA, in this case defined as being either undifferentiated arthritis (UA) or RA) diagnosis. Longitudinal cohort data were used from two CSA cohorts (n = 507) and an IA cohort (n = 282). HRQoL as measured with the EuroQol-5 Dimensions-5 levels (EQ-5D-5 L) questionnaire was compared between CSA patients who develop IA and who do not. We estimated the course of EQ-5D-5 L scores with linear mixed models. In addition, autoantibody-positive and -negative patients were compared. As patients developed IA, their mean EQ-5D-5 L scores deteriorated with 0.12 points (0.03-0.22) over two years, with mobility and usual activities most impacted. Self-care and pain/discomfort were already impacted longer before the diagnosis. Treatment initiation after IA diagnosis showcased an improvement of 0.13 (0.09-0.16) points within 4 months, particularly in the self-care and pain/discomfort dimensions, stabilizing thereafter. In CSA patients who did not develop IA, HRQoL remained stable with a minor improvement of 0.05 (0.02-0.08) points over 2 years. Autoantibody-status had no impact. HRQoL deteriorates before IA diagnosis but improves after treatment initiation. CSA patients who do not develop IA experience stable HRQoL. These findings suggest that early intervention in CSA could prevent deterioration in HRQoL, supporting the potential value of treatment in the CSA phase.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"112"},"PeriodicalIF":3.2,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12009239/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143992350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of treatment with janus kinase inhibitors on coronary microvascular perfusion in patients with rheumatoid arthritis: an observational prospective cohort study.","authors":"Panagiota Anyfanti, Elena Angeloudi, Eleni Pagkopoulou, Maria Boutel, Georgia-Savina Moysidou, Kleopatra Deuteraiou, Eleni Bekiari, Michael Doumas, George D Kitas, Theodoros Dimitroulas","doi":"10.1007/s00296-025-05862-y","DOIUrl":"10.1007/s00296-025-05862-y","url":null,"abstract":"<p><p>Despite their increasing use and their proven efficacy in the treatment of rheumatoid arthritis (RA), Janus kinase (JAK) inhibitors have been questioned by credible cardiovascular safety concerns. To date, mechanistic links of cardiovascular complications to JAK inhibitors remain largely unexplored. We aimed to investigate the effect of JAK inhibition on coronary microvascular blood flow in a previously published cohort of treated patients with RA. We prospectively enrolled RA patients initiating treatment with JAK inhibitors. Study procedures were performed at baseline and repeated 3 months after treatment. Patients underwent applanation tonometry in the radial artery to assess subendocardial viability ratio (SEVR) otherwise known as Buckberg index, a noninvasive marker of myocardial perfusion. Thirteen patients with RA were enrolled, of whom 11 completed the study. All patients presented with at least one cardiovascular risk factor (e.g., age ≥ 65 years, history of current or past smoking, obesity, hypertension). No change in other than antirheumatic treatment was performed during the study, and no significant changes were observed in baseline characteristics other than triglyceride levels. Compared to baseline, three months treatment with JAK inhibitors did not significantly alter SEVR values [126 (102-144) % vs. 134 (106-251) %, p = 0.083]. Three months treatment with JAK inhibitors did not seem to significantly affect myocardial perfusion in a small RA cohort with cardiovascular risk factors, who would be presumably more vulnerable to adverse treatment-related cardiovascular effects. Larger studies with longer follow-up are needed to document the effects of JAK inhibitors on the myocardium.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"111"},"PeriodicalIF":3.2,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12009227/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144045475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High long-term retention rates of Secukinumab in psoriatic arthritis and ankylosing spondylitis: a 3-year interim analysis from the observational, prospective SERENA study, in Greek patients.","authors":"Andreas Bounas, Anna Kandyli, Gkikas Katsifi, Dimitrios Boumpa, Maria G Tektonidou, Sousana Gazi, Anastasios Kotrotsios, Lazaros I Sakkas, Athanasios N Georgiadis, Loukas Settas, Xenia Madia, Dimitra Ignatiadi, Petros P Sfikakis","doi":"10.1007/s00296-025-05839-x","DOIUrl":"10.1007/s00296-025-05839-x","url":null,"abstract":"<p><p>SERENA is a recently completed, non-interventional, multinational, 5-year study evaluating retention, effectiveness, patient-reported outcomes and safety of secukinumab in patients with moderate-to-severe psoriasis, active psoriatic arthritis (PsA), and active ankylosing spondylitis (AS) treated in real-world settings. Three-year interim data from PsA and AS patients treated in Greek centres are presented herein. PsA and AS adults receiving secukinumab per the approved label for ≥ 16 weeks were included. Overall, 214 PsA and 81 AS eligible patients were enrolled, with mean age of 53.0 and 48.2 years and mean disease duration of 7.5 and 9.1 years, respectively. Of PsA and AS patients, 73.4% and 56.8% were bio-experienced, respectively. Secukinumab retention rates at 1, 2, and 3 years post-enrolment were 87.1%, 76.9%, and 74.0% in PsA and 89.9%, 80.5%, and 77.3% in AS patients, respectively. Main reasons for drug discontinuation were lack of effectiveness (37.1%) and adverse event (AE; 27.1%). The safety set (patients with at least 1 secukinumab dose after signing the informed consent) included 218 PsA and 81 AS patients, of whom 13.3% and 13.6% experienced secukinumab-related AEs, respectively. One malignancy was reported. No candida infections, major adverse cardiovascular events, inflammatory bowel disease or uveitis were reported. In conclusion, similarly high persistence to secukinumab was observed for both PsA and AS after 3 years of observation, with a favourable safety profile.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"105"},"PeriodicalIF":3.2,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12008057/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144028141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mental Ill-Health in young people with systemic autoinflammatory disease - a scoping review.","authors":"Amanda Clarke, Caitlin McDowell, Paul Badcock","doi":"10.1007/s00296-025-05864-w","DOIUrl":"10.1007/s00296-025-05864-w","url":null,"abstract":"<p><p>Systemic autoinflammatory disorders (SAID), immune dysregulation disorders with onset frequently occurring in youth, are defined by unprovoked inflammation. Research suggest inflammation is associated with the pathogenesis of mental ill-health. Separately, research has identified that mental ill-health is prevalent in people with immune dysregulation disorders compared to healthy controls or those with other chronic diseases, and the psychosocial impacts of these diseases on quality of life can be debilitating. This review aimed to broadly identify the extent and nature of research involving young people with SAIDs and mental ill-health. A scoping review was conducted across 6 databases of peer-reviewed articles referring to SAIDs and mental ill-health in young people. Of 727 studies, 41 met the inclusion criteria. Thirty-seven were observational studies, including 18 case studies or series. Four studies were treatment trials. Fourteen observational studies investigated the prevalence of mental ill-health in a SAID population with large sample sizes. Most studies were conducted in Türkiye, involving Behçet's syndrome or familial Mediterranean fever and anxiety, depression, and psychosis were strongly represented. Findings suggest an association between mental ill-health and SAID activity in young people. Anxiety and depression were associated with some specific SAIDs duration, symptom severity, SAID flare recency and frequency, and SAID treatment effects. Co-occurrence and resolution of SAID flares and mental ill-health with treatment were frequent themes in case studies of some SAIDs. Further research is required on the prevalence and risk of developing mental ill-health among young people with SAIDs, along with associations between mental ill-health, other SAIDs and disease activity, other participant variables, and appropriate management of mental ill-health in this population.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"108"},"PeriodicalIF":3.2,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12008080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144029183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of proprotein convertase subtilisin/kexin type 9 inhibitors in managing hypercholesterolemia post-statin-associated immune-mediated necrotizing myopathy: report of five cases and literature review.","authors":"Melina Yerolatsite, Nanteznta Torounidou, Nafsika Gerolymatou, Aikaterini Panteli, Nikolaos Koletsos, Maria Karakosta, George Zarkavelis, Paraskevi V Voulgari","doi":"10.1007/s00296-025-05860-0","DOIUrl":"10.1007/s00296-025-05860-0","url":null,"abstract":"<p><p>Immune-mediated necrotizing myopathy (IMNM), a type of inflammatory myopathy, is associated with anti-SRP or anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (anti-HMGCR) antibodies, with statin use potentially inducing statin-associated IMNM (SAIMNM) due to HMGCR targeting. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors may offer a safer alternative for lipid-lowering in these patients. This study aims to describe the clinical characteristics of SAIMNM patients and evaluate the safety of PCSK9 inhibitors after myositis onset. We present the clinical characteristics of five SAIMNM patients and evaluate the safety of PCSK9 inhibitors in these cases. Additionally, we conducted a literature review using four different databases (Medline/PubMed, Scopus, Cochrane and DOAJ) to summarize the available data on IMNM. While numerous articles discussed statin-induced myositis, we selected only those studies that addressed the treatment of dyslipidemia after the management of IMNM. All five patients were women, with four having a history of statin use. One statin-naïve patient was positive for anti-SRP antibodies, while the others had anti-HMGCR antibodies. After a mean follow-up of 18.2 months, creatine phosphokinase (CPK) levels dropped from 1028.6 IU/L to 135 IU/L, and LDL cholesterol levels decreased from 206.2 mg/dL to 87.2 mg/dL. All patients were treated with steroids (with a gradual dosage reduction), and four of the five received second line immunosuppressive therapy, such as intravenous immunoglobulin, methotrexate, azathioprine, and mycophenolate mofetil. No disease recurrence occurred after starting PCSK9 inhibitors. A review of seven studies (15 patients) showed a mean CPK of 1531.9 IU/L. 40% received steroids and another immunosuppressant. Statin rechallenge caused relapse in two cases, but PCSK9 inhibitors were well tolerated, with only one patient needing additional immunosuppression. Additionally, ezetimibe and bempedoic acid were used successfully in some patients. Finally, lipid levels appeared to be lower after treatment with PCSK9 inhibitors. Administration of PCSK9 inhibitors appears to be an effective and safe option for the treatment of dyslipidaemia in patients with IMNM.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"109"},"PeriodicalIF":3.2,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12008069/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144034674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Validity and psychometric characteristics of the Duruöz Hand Index (DHI) in patients with systemic sclerosis.","authors":"Mehmet Tuncay Duruöz, Nuran Öz, Yusuf Karabulut, Didem Erdem Gürsoy, Halise Hande Gezer, Sevtap Acer Kasman","doi":"10.1007/s00296-025-05844-0","DOIUrl":"10.1007/s00296-025-05844-0","url":null,"abstract":"","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 5","pages":"110"},"PeriodicalIF":3.2,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12008073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144054278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}